In a July 5 press release, AstraZeneca said TeneoTwo’s “promising” T-cell engager is designed to redirect the immune system to “recognize and kill cancer cells.”
“We believe this innovative molecule, which was designed to optimize the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting,” AstraZeneca’s senior vice president of hematology research and development, Anas Younes, MD, said in a statement.
The transaction is set to finalize at the end of the third quarter of 2022.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
